The Hunger Hormone Ghrelin: Why Your Body Fights Every Diet

In 1999, a team of researchers in Tokyo led by Masayasu Kojima was looking for the natural ligand of an orphan receptor — one of those signalling docks whose hormone partner had not yet been identified. They isolated the molecule from rat stomach extracts, sequenced it, and tested what it did. When they injected it into rats, the animals ate more. A great deal more. The substance had no precedent in mammalian endocrinology: a peripheral hormone whose primary action was to drive appetite up rather than down.

They named it ghrelin, from the Proto-Indo-European root ghre-, meaning to grow. The discovery, published in Nature, opened a research programme that has since reshaped the way obesity medicine understands hunger — and the way researchers think about why diets so reliably fail.

What ghrelin actually does

Ghrelin is produced mostly by specialised cells in the stomach lining, with smaller contributions from the small intestine and pancreas. It circulates in the blood and acts on receptors in the hypothalamus — specifically on the arcuate nucleus, the brain region that integrates hunger and satiety signals. When ghrelin binds those receptors, the neurons that drive food-seeking behaviour fire harder. The conscious experience is hunger.

Ghrelin is the only peripheral hormone identified to date whose primary appetite effect is orexigenic — appetite-stimulating. Dozens of hormones suppress appetite to varying degrees. Only one, in the body's known catalogue, actively generates hunger from the gut side.

This asymmetry matters. The body has built considerable redundancy into the systems that prevent overeating in the short term. The systems that prevent undereating — that drive the search for food when energy stores are at risk — converge largely on a single hormone. Ghrelin is the system's loudest voice saying eat.

The pre-meal pattern

David Cummings at the University of Washington published the first detailed human time-series of ghrelin secretion in 2001. His team sampled blood every five minutes for twenty-four hours in healthy adults eating three meals at fixed times. The pattern was striking. Ghrelin climbed steadily in the hour or two before each scheduled meal, peaked just before eating, and dropped sharply after the meal began. The rise tracked subjective hunger almost exactly.

What this revealed is that hunger before meals is not a passive emptying of the stomach. It is an active hormonal signal that anticipates eating, triggered in part by habitual meal timing. The body learns when you eat and starts asking for food in advance. Skip the meal and ghrelin keeps climbing until it does fall on its own — but the falling, in chronic restriction, does not mean the system has accepted the new pattern. It means a temporary hormonal recalibration that the body subsequently undoes.

What happens to ghrelin after weight loss

Cummings's 2002 paper in the New England Journal of Medicine changed how the field talks about dieting. His team measured ghrelin in adults who had lost an average of 17% of their body weight through a six-month dietary programme. Three months after weight loss ended — with weight stable — ghrelin levels were significantly elevated above pre-diet baseline. Not lower, as the smaller body might predict. Higher.

The pre-meal peaks were larger. The 24-hour profile was elevated. The biological driver of hunger had been turned up.

Priya Sumithran in Melbourne extended this work in a 2011 paper that has become one of the most-cited references in obesity medicine. Her team tracked ten appetite-regulating hormones in fifty adults across a year following a very-low-calorie diet. At twelve months, ghrelin remained roughly 20% above the pre-diet baseline. Peptide YY, cholecystokinin, and other satiety hormones remained suppressed. Subjective hunger remained elevated. The hormonal environment of a person who had successfully lost weight was, a year later, an environment that biologically favoured regaining it.

The dieted body is not the same hormonal animal as the never-dieted body of equivalent weight. This is one of the most important findings to come out of obesity research in the past three decades, and it explains a great deal that older behavioural models could not.

Why the body holds on to this elevation

From an evolutionary standpoint, this is not a malfunction. For most of human history, the loss of significant body weight signalled either famine or disease. A system that responded to weight loss by ramping up hunger and conserving energy was a system that kept its owners alive. The same machinery that protected a Pleistocene human from a bad season now defends modern weight loss against modern intentions.

Ghrelin sits at the front of that defence. It is not a flaw in the system. It is a feature whose context has changed.

Why willpower cannot override a hormone

The cultural framing of dieting tends to assume that the difficulty is moral: a sufficiently determined person will resist the cookies. The evidence suggests this assumption was built on incomplete biology. Ghrelin acts on a brain circuit whose function is to generate the motivation to find and consume food when energy is low. It does not announce itself as a hormone. It announces itself as a feeling — hunger, restlessness, intrusive thoughts about specific foods, the sense that something is missing.

People can override this for a while. The capacity to resist immediate biological drives is one of the things that distinguishes the prefrontal cortex from the brainstem. But sustained resistance to an elevated hormonal driver is metabolically and psychologically expensive, and the evidence from long-term weight loss maintenance trials shows that most people, given enough time, lose the battle. Not because they tried less hard, but because the opposing signal kept being generated, day after day, indefinitely.

This is the heart of why diets fail biologically. The intervention asks behaviour to fight hormones. The hormones do not get tired.

Where pharmacology enters

The conceptual breakthrough behind GLP-1 medications was the recognition that obesity treatment had to address the hormonal environment, not just the behaviour layered on top of it. Semaglutide and tirzepatide do not directly lower ghrelin. They work primarily through the satiety side of the equation — enhancing GLP-1 and, for tirzepatide, GIP signalling — and through the brain's reward circuitry. But the net effect is a hormonal environment that the brain reads as adequately fed, even in caloric deficit.

The asymmetry is the point. Diets create caloric deficit while leaving the hunger machinery to escalate against it. GLP-1 medications create caloric deficit while modulating the hunger machinery so that the escalation doesn't happen at the same intensity. The same weight loss, biologically defended against in one case and not in the other.

What this means in practice

For anyone who has lost weight and watched it return — and watched themselves blamed, or blamed themselves, for that return — the ghrelin story is worth holding on to. It is not the whole story; leptin resistance, adaptive thermogenesis, NEAT reduction, and reward circuitry all matter. But it is the part of the story where the science is clearest. The hormone exists. Its trajectory after weight loss has been measured. It does not return to baseline on its own.

Treating obesity as a chronic disease — one that requires ongoing management rather than a temporary intervention — follows from this evidence, not from ideology. The hormone is still elevated a year later. The next year too.

Key takeaways

• Ghrelin, discovered by Kojima's team in Tokyo in 1999, is the only known peripheral hormone whose primary action is to increase hunger.
• Ghrelin levels rise before habitual meals and fall after eating — closely tracking subjective hunger throughout the day.
• After weight loss, ghrelin rises above pre-diet baseline and remains elevated. Sumithran's 12-month data showed roughly 20% elevation persisting alongside suppressed satiety hormones.
• The elevation is a defended biological response, not a malfunction — energy loss historically signalled famine, and the system evolved to push back.
• Sustained behavioural restraint against an elevated hormonal driver is the structural reason most diets fail long-term.
• GLP-1 receptor agonists shift the broader hormonal environment toward satiety, reducing the asymmetry that diets create.